Clinical Trial Update: Safety, Tolerability and Pharmacokinetics of GSK1034702 in Healthy Subjects [Phase 1]

View source ↗

Summary

Phase 1 study of GSK1034702 in healthy subjects assessing safety, tolerability and pharmacokinetics has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cognitive Disorders

Drugs mentioned

• GSK1034702

Snippet

Sponsor: GlaxoSmithKline | Conditions: Cognitive Disorders | Phase 1 | Status: COMPLETED